Skip to main content

Table 1 Clinical trials of anti-BCMA CAR-T cells for MM

From: Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma

Institution

NCI

Upenn

Bluebird Multi-Inst (Bb2121)

Nanjing Legend (LCAR-B38M)

MSK

Scfv derived from

Murine hybridoma

Human library

Murine hybridoma

Murine hybridoma

Human library

Co-stimulatory domain

CD28

4-1BB

4-1BB

4-1BB

4-1BB

Gene transfer

Retrovirus

Lentivirus

Lentivirus

Lentivirus

Retrovirus

Conditioning

Cy + Flu

Cohort 1: none

Cohorts 2 and 3: Cy

Cy + Flu

Cy

Cy + Flu

BCMA Ag required

> 50%

No requirement

> 50%

“Clear expression”

> 1%

ClinicalTrials.gov identifier/reference

NCT022159679,10

NCT0254616727

NCT0265892928

NCT0309065929

NCT03070327

Median prior lines

7

9

7

3

Not yet reported

Accrual

Completed (26 patients)

Completed (24 patients, data reported)

Ongoing (21 patients, data reported)

Ongoing (19 patients, data reported)

Not yet reported

Response

13 Of 16 (81%) ORR at highest dose

6 Of 10 (60%) ORR at high dose with Cy conditioning

17 Of 18 (94%) ORR at higher doses

19 Of 19 (100%) ORR

Not yet reported

Elimination gene

No

No

No

No

Truncated EGFR

  1. NCI National Cancer Institute, UPenn University of Pennsylvania, MSK Memorial Sloan Kettering, scFv single chain variable fragment, Cy + Flu cyclophosphamide+ fludarabine